Person: Juarranz Moratilla, Yasmina
Loading...
First Name
Yasmina
Last Name
Juarranz Moratilla
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Ciencias Biológicas
Department
Biología Celular
Area
Biología Celular
Identifiers
6 results
Search Results
Now showing 1 - 6 of 6
Item Vasoactive intestinal peptide in early spondyloarthritis: low serum levels as a potential biomarker for disease severity(Journal of Molecular Neuroscience, 2015) Valiño Seoane, Iria; Tomero, Eva; Martínez Mora, María Del Carmen; Garcia-Vicuña, Rosario; Juarranz Moratilla, Yasmina; Lamana Domínguez, Amalia; Ocón, Elena; Ortiz, Ana M.; Gómez-León, Nieves; González-Álvaro, Isidoro; Pérez-Gomáriz, RosaSpondyloarthritis (SpA) is a family of inflammatory diseases sharing clinical, genetic, and radiological features. While crucial for tailoring early interventions, validated prognostic biomarkers are scarce in SpA. We analyze the correlation between serum levels of vasoactive intestinal peptide (VIP) and disease activity/severity in patients with early chronic inflammatory back pain. The study population comprised 54 patients enrolled in our early chronic inflammatory back pain register. We collected demographic information, clinical data, laboratory data, and imaging findings. VIP levels were measured by enzyme immunoassay in serum samples from 162 visits. The association between independent variables and VIP levels was analyzed using longitudinal multivariate analysis nested by patient and visit. No significant differences were observed in VIP levels between these two groups. Lower levels of VIP were significantly associated with a higher Bath Ankylosing Spondylitis Disease Activity Index (BASFI) score, presence of bone edema in magnetic resonance imaging (MRI) scan, and lower hemoglobin levels. Coexistence of cutaneous psoriasis was independently associated with lower VIP levels, and similar trend was observed for enthesitis.We conclude that SpA patients with low serum VIP levels had worse 2-year disease outcome, suggesting that serum VIP levels could be a valid prognostic biomarker.Item The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP(Journal of Molecular Medicine, 2015) Jimeno Lumeras, Rebeca Gema; Pérez Gomáriz, Rosa María; Garín, Marina I.; Gutiérrez Cañas, Irene; González Álvaro, Isidoro; Carrión Caballo, Mar; Galindo, María; Leceta Martínez, Javier; Juarranz Moratilla, YasminaOur aim is to study the behavior of memory Th cells (Th17, Th17/1, and Th1 profiles) from early rheumatoid arthritis (eRA) patients after their in vitro activation/expansion to provide information about its contribution to RA chronicity. Moreover, we analyzed the potential involvement of vasoactive intestinal peptide (VIP) as an endogenous healing mediator. CD4+CD45RO+ T cells from PBMCs of HD and eRA were activated/expanded in vitro in the presence/absence of VIP. FACS, ELISA, RT-PCR, and immunocytochemistry analyseswere performed. An increase in CCR6+/RORC+ cells and in RORC-proliferating cells and a decrease in T-betproliferating cells and T-bet+/RORC+ cells were shown in eRA. mRNA expression of IL-17, IL-2, RORC, RORA, STAT3, and Tbx21 and protein secretion of IL-17, IFNγ, and GM-CSF were higher in eRA. VIP decreased the mRNA expression of IL-22, IL-2, STAT3, Tbx21, IL-12Rβ2, IL-23R, and IL-21R in HD and it decreased IL-21, IL-2, and STAT3 in eRA. VIP decreased IL-22 and GM-CSF secretion and increased IL-9 secretion in HD and it decreased IL-21 secretion in eRA. VPAC2/VPAC1 ratio expression was increased in eRA. All in all, memory Th cells from eRA patients show a greater proportion of Th17 cells with a pathogenic Th17 and Th17/1 profile compared to HD. VIP is able to modulate the pathogenic profile, mostly in HD. Our results are promising for therapy in the early stages of RA because they suggest that targeting molecules involved in the pathogenic Th17, Th17/1, and Th1 phenotypes and targeting VIP receptors could have a therapeutic effect modulating these subsets.Item The Neuropeptide VIP Limits Human Osteoclastogenesis: Clinical Associations with Bone Metabolism Markers in Patients with Early Arthritis(Biomedicines, 2021) Castro Vázquez, David; Lamana Rodríguez, Amalia; Arribas Castaño, Paula; Gutiérrez Cañas, Irene; Villanueva Romero, Raúl; Pérez García, Selene; Martínez Mora, María Del Carmen; Juarranz Moratilla, Yasmina; Fernández de Córdoba, Sara; González Álvaro, Isidoro; Gomáriz, Rosa P.; Carrión Caballo, MarWe aimed to evaluate the direct action of VIP on crucial molecules involved in human osteoclast differentiation and function. We also investigated the relationship between VIP serum levels and bone remodeling mediators in early arthritis patients. The expression of VIP receptors and osteoclast gene markers in monocytes and in vitro differentiated osteoclasts was studied by real-time PCR. NFATc1 activity was measured using a TransAM® kit. Osteoclastogenesis was confirmed by quantification of tartrate-resistant acid phosphatase positive multinucleated cells. OsteoAssay® Surface Multiple Well Plate was used to evaluate bone-resorbing activity. The ring-shaped actin cytoskeleton and the VPAC1 and VPAC2 expression were analyzed by immunofluorescence. We described the presence of VIP receptors in monocytes and mature osteoclasts. Osteoclasts that formed in the presence of VIP showed a decreased expression of osteoclast differentiation gene markers and proteolytic enzymes involved in bone resorption. VIP reduced the resorption activity and decreased both β3 integrin expression and actin ring formation. Elevated serum VIP levels in early arthritis patients were associated with lower BMD loss and higher serum OPG concentration. These results demonstrate that VIP exerts an anti-osteoclastogenic action impairing both differentiation and resorption activity mainly through the negative regulation of NFATc1, evidencing its bone-protective effects in humans.Item Vasoactive intestinal peptide exerts an osteoinductive effect in human mesenchymal stem cells(BioFactors, 2024) Castro Vázquez, David; Arribas Castaño, Paula; García López, Iván; Gutiérrez Cañas, Irene; Pérez García, Selene; Lamana Domínguez, Amalia; Villanueva Romero, Raúl; Cabrera Martín, Alicia; Tecza , Karolina; Martínez Mora, María Del Carmen; Juarranz Moratilla, Yasmina; Pérez Gomáriz, Rosa María; Carrión Caballo, MarSeveral neuropeptides present in bone tissues, produced by nerve fibers and bone cells, have been reported to play a role in regulating the fine-tuning of osteoblast and osteoclast functions to maintain bone homeostasis. This study aims to characterize the influence of the neuropeptide vasoactive intestinal peptide (VIP) on the differentiation process of human mesenchymal stem cells (MSCs) into osteoblasts and on their anabolic function. We describe the mRNA and protein expression profile of VIP and its receptors in MSCs as they differentiate into osteoblasts, suggesting the presence of an autocrine signaling pathway in these cells. Our findings reveal that VIP enhances the expression of early osteoblast markers in MSCs under osteogenic differentiation and favors both bone matrix formation and proper cytoskeletal reorganization. Finally, our data suggest that VIP could be exerting a direct modulatory role on the osteoblast to osteoclast signaling by downregulating the receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio. These results highlight the potential of VIP as an osteoinductive differentiation factor, emerging as a key molecule in the maintenance of human bone homeostasis.Item Proteomic analysis of synovial fibroblasts and articular chondrocytes co-cultures reveals valuable VIP-modulated inflammatory and degradative proteins in osteoarthritis(International Journal of Molecular Sciences, 2021) Pérez García, Selene; Calamia, Valentina; Hermida-Gómez, Tamara; Gutiérrez Cañas, Irene; Carrión Caballo, Mar; Villanueva Romero, Raúl; Castro Vázquez, David; Martínez Mora, María Del Carmen; Juarranz Moratilla, Yasmina; Blanco, Francisco J.; Pérez Gomáriz, Rosa MaríaOsteoarthritis (OA) is the most common musculoskeletal disorder causing a great disability and a reduction in the quality of life. In OA, articular chondrocytes (AC) and synovial fibroblasts (SF) release innate-derived immune mediators that initiate and perpetuate inflammation, inducing cartilage extracellular matrix (ECM) degradation. Given the lack of therapies for the treatment of OA, in this study, we explore biomarkers that enable the development of new therapeutical approaches. We analyze the set of secreted proteins in AC and SF co-cultures by stable isotope labeling with amino acids (SILAC). We describe, for the first time, 115 proteins detected in SF-AC co-cultures stimulated by fibronectin fragments (Fn-fs). We also study the role of the vasoactive intestinal peptide (VIP) in this secretome, providing new proteins involved in the main events of OA, confirmed by ELISA and multiplex analyses. VIP decreases proteins involved in the inflammatory process (CHI3L1, PTX3), complement activation (C1r, C3), and cartilage ECM degradation (DCN, CTSB and MMP2), key events in the initiation and progression of OA. Our results support the anti-inflammatory and anti-catabolic properties of VIP in rheumatic diseases and provide potential new targets for OA treatment.Item Vasoactive intestinal peptide axis is dysfunctional in patients with Graves’ disease(Scientific reports, 2020) Carrión Caballo, Mar; Ramos-Levi, A. M.; Valiño Seoane, Iria; Martínez Hernández, R.; Serrano-Somavilla, A.; Castro Vázquez, David; Juarranz Moratilla, Yasmina; González Álvaro, I.; Gomáriz, Rosa P.; Marazuela, MónicaVasoactive intestinal peptide (VIP) is a neuropeptide with potent immunoregulatory properties. Reduced serum VIP levels and alterations in VIP receptors/signaling on immune cells have been associated with diferent infammatory/autoimmune diseases. However, its role in autoimmune thyroid diseases (AITD) remains unknown. This study examined the interrelationship between VIP system, autoimmune background and thyroid hormones in peripheral immune cells in patients with AITD. Only Graves’ disease (GD) patients showed signifcantly lower serum VIP levels when compared to healthy subjects and to Hashimoto’s thyroiditis patients. Serum VIP levels were lower at the onset of GD, showing a signifcant negative correlation with thyroid hormone levels. The expression of VIP receptors, VPAC1 and VPAC2, was signifcantly upregulated in peripheral blood mononuclear cells (PBMC) from GD patients. There was an impairment of VIP signalling in these patients, probably attributable to a dysfunction of VPAC1 with preservation of VPAC2. The correlation between VPAC1 and thyroid hormone receptor expression in PBMC from healthy subjects was lost in GD patients. In summary, the VIP system is altered in peripheral immune cells of GD patients and this fnding is associated with diferent thyroid hormone receptor patterns, showing a dynamic inter-regulation and a prominent role of VIP in this setting.